Signaling networks in cholangiocarcinoma molecular pathogenesis, targeted therapies and drug resistance

Abstract : Cholangiocarcinoma (CCA) is a deadly disease. While surgery may attain cure in a minor fraction of cases, therapeutic options in either the adjuvant or advanced setting are limited. The possibility of advancing the efficacy of therapeutic approaches to CCA relies on understanding its molecular pathogenesis and developing rational therapies aimed at interfering with oncogenic signaling networks that drive and sustain cholangiocarcinogenesis. These efforts are complicated by the intricate biology of CCA, which integrates not only the driving force of tumor-cell-intrinsic alterations at the genetic and epigenetic level, but also pro-tumorigenic cues conveyed to CCA cells by different cell types present in the rich tumor stroma. Herein, we review our current understanding of the mechanistic bases underpinning the activation of major oncogenic pathways causative of CCA pathogenesis. We subsequently discuss how this knowledge is being exploited to implement rationale-based and genotype-matched therapeutic approaches that predictably will radically transform CCA clinical management in the next decade. We conclude by highlighting mechanisms of therapeutic resistance in CCA and reviewing innovative approaches to combat resistance at the pre-clinical and clinical level.
Complete list of metadatas

Cited literature [219 references]  Display  Hide  Download

https://hal-univ-rennes1.archives-ouvertes.fr/hal-02087897
Contributor : Laurent Jonchère <>
Submitted on : Friday, June 14, 2019 - 10:21:00 AM
Last modification on : Thursday, June 27, 2019 - 1:18:06 PM

File

 Restricted access
To satisfy the distribution rights of the publisher, the document is embargoed until : 2019-09-23

Please log in to resquest access to the document

Identifiers

Citation

Laura Fouassier, Marco Marzioni, Marta B Afonso, Steven Dooley, Kevin Gaston, et al.. Signaling networks in cholangiocarcinoma molecular pathogenesis, targeted therapies and drug resistance. Liver International, Wiley-Blackwell, 2019, Cholangiocarcinoma, 39 (S1), pp.43-62. ⟨10.1111/liv.14102⟩. ⟨hal-02087897⟩

Share

Metrics

Record views

25